Skip to main content
Stacey Rifkin-Zenenberg, DO, Pediatric Hematology & Oncology, Hackensack, NJ

Stacey Rifkin-Zenenberg DO FAAP, FAAHPM


Section Chief, Pediatric Pain and Palliative Care, Pediatric Hematologist/Oncologist

Join to View Full Profile
  • 30 Prospect AveHackensack, NJ 07601

  • Phone+1 551-996-5437

  • Fax+1 201-487-7340

Dr. Rifkin-Zenenberg is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Summary

  • Dr. Stacey Rifkin-Zenenberg is a pediatric hematologist/oncologist based in Hackensack, NJ. She completed her residency in pediatrics at Rutgers Health/Newark Beth Israel Medical Center and her fellowship in pediatric hematology/oncology at Zucker School of Medicine. Dr. Rifkin-Zenenberg currently serves as the Section Chief, Pediatric Pain and Palliative Care at Joseph Sanzari Children’s Hospital, where she also practices as a pediatric hematologist/oncologist. She has prior experience at Newark Beth Israel Medical Center. She is recognized for contributions to significant publications such as "Rate of thrombosis in children and adolescents hospitalized with COVID-19 or MIS-C", and "Biologic and Clinical Efficacy of LentiGlobin for Sickle Cell Disease", among others. She has also participated in several clinical trials related to sickle cell disease and B-cell NHL. She is a Fellow of American Academy of Pediatrics (FAAP).

Education & Training

  • Zucker School of Medicine at Hofstra/Northwell at Cohen Children's Medical Center
    Zucker School of Medicine at Hofstra/Northwell at Cohen Children's Medical CenterFellowship, Pediatric Hematology/Oncology, 1998 - 2001
  • Rutgers Health/Newark Beth Israel Medical Center
    Rutgers Health/Newark Beth Israel Medical CenterResidency, Pediatrics, 1995 - 1998
  • Philadelphia College of Osteopathic Medicine
    Philadelphia College of Osteopathic MedicineClass of 1995

Certifications & Licensure

  • NJ State Medical License
    NJ State License 1997 - 2027
  • NY State Medical License
    NY State License 1997 - 2026
  • PA State Medical License
    PA State License 1997 - 2005
  • Pediatrics
    American Board of Pediatrics Pediatrics
  • Hospice and Palliative Medicine
    American Board of Pediatrics Hospice and Palliative Medicine
  • Pediatric Hematology-Oncology
    American Board of Pediatrics Pediatric Hematology-Oncology
  • Full Member
    American Academy of Medical Acupuncture Full Member
  • Certificate Program in Pediatric BioEthics of the Children's Mercy BioEthics Center
    Children's Mercy Hospital/University of Missouri-Kansas City School of Medicine Certificate Program in Pediatric BioEthics of the Children's Mercy BioEthics Center

Awards, Honors, & Recognition

  • Fellow, FAAHPM American Academy of Hospice and Palliative Medicine, 2024
  • Fellow (FAAP) American Academy of Pediatrics

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • First Patient Treated with Federally Approved Lyfgenia™ for the Curative Gene Therapy Treatment of Sickle Cell Disease Leaves Joseph M. Sanzari Children’s Hospital at Hackensack University Medical Center
    First Patient Treated with Federally Approved Lyfgenia™ for the Curative Gene Therapy Treatment of Sickle Cell Disease Leaves Joseph M. Sanzari Children’s Hospital at Hackensack University Medical CenterJune 6th, 2025
  • New Jersey Teen Pain-Free Thanks to New Sickle Cell Disease Treatment
    New Jersey Teen Pain-Free Thanks to New Sickle Cell Disease TreatmentMay 26th, 2025
  • Bluebird Bio to Present Additional Long-Term Follow-up Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition
    Bluebird Bio to Present Additional Long-Term Follow-up Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 66th American Society of Hematology (ASH) Annual Meeting and ExpositionNovember 5th, 2024
  • Join now to see all

Professional Memberships

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: